Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
First Claim
1. An immunotherapeutic composition, comprising activated, isolated antigen presenting cells (APCs), wherein said APCs are obtained from a patient diagnosed with a cancer having a moderate to well differentiated cancer grade and wherein said APCs are stimulated by exposure ex vivo to a tumor-associated antigen (TAA).
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are immunotherapeutic compositions and methods for the treatment of cancers characterized by the presence of moderately to well-differentiated cancer cells. Exemplary immunotherapeutic compositions employ antigen presenting cells, including dendritic cells, activated by a protein conjugate such as fusion proteins including a prostatic acid phosphatase/granulocyte-macrophage colony stimulation factor fusion protein. Also disclosed are methods for assessing the susceptibility of cancer cells to treatment regimens employing one or more immunotherapeutic composition.
-
Citations
30 Claims
- 1. An immunotherapeutic composition, comprising activated, isolated antigen presenting cells (APCs), wherein said APCs are obtained from a patient diagnosed with a cancer having a moderate to well differentiated cancer grade and wherein said APCs are stimulated by exposure ex vivo to a tumor-associated antigen (TAA).
-
21. A method of treating a cancer patient with an immunotherapeutic composition said patient having a cancer with moderately to well-differentiated cancer cells, said method comprising the steps of:
-
(a) determining in said patient the differentiation state of said cancer cells wherein the presence of moderately to well-differentiated cancer cells indicates a patient susceptible to treatment with an immunotherapeutic composition; and
(b) administering to said patient a therapeutically effective dose of an immunogenic composition, wherein a reduction of 10% indicates an effective treatment of said cancer.
-
-
23. A method of inhibiting growth of a cancer cell in a patient having a moderate to well differentiated cancer grade, said method comprising the steps of:
-
(a) determining in said patient the grade of said cancer cell wherein a moderate to well differentiated cancer grade indicates a patient susceptible to treatment;
(b) isolating antigen presenting cells (APCs) from a patient having a moderate to well differentiated cancer grade;
(c) stimulating said APCs by exposure ex vivo to an immunotherapeutic composition comprising a protein conjugate comprising an N-terminal moiety and a C-terminal moiety, wherein said APCs are effective to activate T-cells to produce a cytotoxic cellular response against either said N-terminal moiety or said C-terminal moiety and wherein the level of said T-cell activation is higher than that produced by said APCs when exposed exclusively to said N-terminal moiety or to said C-terminal moiety; and
(d) administering to said patient a therapeutically effective dose of said stimulated APCs, wherein a reduction of 10% indicates an effective treatment of said cancer. - View Dependent Claims (24, 25, 26)
-
-
28. A method of assessing in a cancer patient the susceptibility of the cancer to an immunotherapeutic composition, said method comprising the steps of:
-
(a) isolating from said patient a sample containing said cancer cell; and
(b) determining the differentiation state of said cancer cell;
wherein a moderate to well differentiated cancer grade indicates that said cancer cell is susceptible to treatment with an immunotherapeutic composition. - View Dependent Claims (29)
-
Specification